Diabetes
| T2D & CGM
Diabetes
T2D & CGM
Once-weekly insulin efsitora alfa and daily degludec achieve comparable glycaemic control in 3 patient populations during phase 2: clinical insights from CGM assessments
book_2
Source:
EASD 2023 - Oral Presentation
calendar_today
Published on Medfyle:
October 2023
import_contacts
5
min
In this medfyle
Once-weekly efsitora achieved similar glycaemic control vs degludec as seen in several CGM derived measures.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the EASD 2023 Annual Meeting. The content is developed by Infomedica in collaboration with the Diabetes Education Study Group (DESG).
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, Medfyle, or the DESG.
©2023 Infomedica-Medfyle. All rights reserved.
